However, CD33-CAR-T cells from AML patients presented an increased proportion of terminal effector (TE) T cells, with higher levels of PD1 and LAG3 exhaustion markers (Figures 2C, D, S3). The gene discussed is CD33; the disease is acute myeloid leukemia.